Johnson & Johnson (JNJ)
J&J plans to invest more than $55 billion in US over next four years
Johnson & Johnson said on Friday it plans to invest more than $55 billion over the next four years to build manufacturing facilities and research infrastructure in the United States.
Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough
Johnson & Johnson JNJ just hit a Golden Cross , a classic bullish technical pattern that signals potential long-term upside. The stock's 50-day simple moving average crossed above its 200-day simple moving average, often seen as a sign of strengthening momentum.
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease in adults.
Resilient Investing: 3 Stocks Built to Weather Market Volatility
As inflationary pressures persist and the specter of a potential recession looms, investors are understandably seeking stability. While predicting market movements is always challenging, focusing on companies with inherent resilience offers a sound strategy for navigating uncertain economic waters.
An AI imaging firm says Johnson & Johnson stole its tech. Execs on both sides are expected to testify next week.
Johnson & Johnson executives are scheduled to take the stand in a trial starting Monday. ChemImage, a small biotech firm, sued the healthcare giant over a 2019 partnership that went south.
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Cramer's Mad Dash: Johnson & Johnson
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
JNJ Halts Development of Depression Drug Over Efficacy Concerns
While J&J is yet to give up on aticaprant, it decides to stop developing the drug for major depressive disorder due to a lack of sufficient efficacy.
3 Dividend Kings Shaking Off Market Woes
While the market throws its tariff tantrum, several long-established companies with years of operational success have seen their shares move higher, displaying relative strength.
J&J to stop late-stage study of add-on depression drug
Johnson & Johnson said on Thursday it will discontinue a late-stage study of its add-on treatment for major depressive disorder due to insufficient efficacy in the target patient population.
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Buy Johnson & Johnson (JNJ) Stock for Higher Highs?
Amid recent market volatility, Johnson & Johnson (JNJ) stock hit new 52-week highs of nearly $170 on Tuesday.
